The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CML/MPN 2025 | Which patients with CML are suitable candidates for receiving asciminib?
In this video, Giuseppe Saglio, MD, University of Turin, Turin, Italy, outlines the two main groups of patients with chronic myeloid leukemia (CML) who are suitable candidates for receiving asciminib – younger and elderly patients. This interview took place at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are two categories of patients, as I told you. One for young patients, because the young patients have clearly very long, I would say, survival expectations, and therefore they need to get rid of the problem of CML, so to be really cured, and we know that this is feasible once that you achieve certain conditions. And so this is particularly important for younger women, particularly young women all over, but particularly maybe in the Middle East or in the Muslim countries, they wanted to start a pregnancy and so they needed to achieve this condition of deep molecular response as soon as possible in order to try to have babies...
There are two categories of patients, as I told you. One for young patients, because the young patients have clearly very long, I would say, survival expectations, and therefore they need to get rid of the problem of CML, so to be really cured, and we know that this is feasible once that you achieve certain conditions. And so this is particularly important for younger women, particularly young women all over, but particularly maybe in the Middle East or in the Muslim countries, they wanted to start a pregnancy and so they needed to achieve this condition of deep molecular response as soon as possible in order to try to have babies.
And the second point is just for the elderly patients, because it’s a very well-tolerated therapy. In this case, maybe the final task is not a TKI discontinuation, but it is a good, very good, I would say, tolerance of the therapy, which is essential not to leave, because one of the main problems is indeed the compliance with the therapy that for elderly patients can be a little bit of a problem as they have many other medications and so on.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
